blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News flashes

New version of the European Patent Register - SPC information for Unitary Patents.

2024-03-06

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP3027183

EP3027183 - SELECTIVE AT2 RECEPTOR AGONISTS FOR USE IN TREATMENT OF CACHEXIA [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  05.07.2019
Database last updated on 12.07.2024
FormerThe patent has been granted
Status updated on  27.07.2018
FormerGrant of patent is intended
Status updated on  22.03.2018
FormerExamination is in progress
Status updated on  26.05.2017
Most recent event   Tooltip01.07.2022Lapse of the patent in a contracting state
New state(s): MK		published on 03.08.2022  [2022/31]
Applicant(s)For all designated states
Anker, Stefan
Oberseestr. 91
13053 Berlin / DE
For all designated states
Coats, Andrew
45 Lyndhurst Street
Richmond, VIC 3121 / AU
[2018/51]
Former [2016/23]For all designated states
Charité - Universitätsmedizin Berlin
Charitéplatz 1
10117 Berlin / DE
Inventor(s)01 / SPRINGER, Jochen
Mainstraße 1b
14612 Falkensee / DE
02 / ANKER, Stefan
Oberseestraße 91
13053 Berlin / DE
03 / COATS, Andrew J.S.
78/151 Fitzroy Street
St. Kilda, Victoria 3168 / AU
 [2016/23]
Representative(s)Gulde & Partner
Patent- und Rechtsanwaltskanzlei mbB
Wallstraße 58/59
10179 Berlin / DE
[2016/23]
Application number, filing date14747861.417.07.2014
[2016/23]
WO2014EP65417
Priority number, dateEP2013017831929.07.2013         Original published format: EP 13178319
[2016/23]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2015014634
Date:05.02.2015
Language:EN
[2015/05]
Type: A1 Application with search report 
No.:EP3027183
Date:08.06.2016
Language:EN
The application published by WIPO in one of the EPO official languages on 05.02.2015 takes the place of the publication of the European patent application.
[2016/23]
Type: B1 Patent specification 
No.:EP3027183
Date:29.08.2018
Language:EN
[2018/35]
Search report(s)International search report - published on:EP05.02.2015
ClassificationIPC:A61K31/4174, A61P43/00, A61K45/06, A61K31/417, A61K31/4178, C07D409/10
[2018/09]
CPC:
A61K31/4178 (EP,US); A61K31/417 (EP,US); A61K45/06 (EP,US);
A61P43/00 (EP); C07D409/10 (EP,US)
C-Set:
A61K31/4178, A61K2300/00 (EP,US)
Former IPC [2016/23]A61K31/4174, A61P43/00
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2016/23]
Extension statesBANot yet paid
MENot yet paid
TitleGerman:SELEKTIVE AT2-REZEPTORAGONISTEN ZUR VERWENDUNG BEI DER BEHANDLUNG VON KACHEXIE[2016/23]
English:SELECTIVE AT2 RECEPTOR AGONISTS FOR USE IN TREATMENT OF CACHEXIA[2016/23]
French:AGONISTES SÉLECTIFS DU RÉCEPTEUR AT2 DESTINÉS À ÊTRE UTILISÉS DANS LE TRAITEMENT DE LA CACHEXIE[2018/09]
Former [2016/23]AGONISTES SÉLECTIFS DU RÉCEPTEUR AT2 POUR UNE UTILISATION DANS LE TRAITEMENT DE LA CACHEXIE
Entry into regional phase06.01.2016National basic fee paid 
06.01.2016Designation fee(s) paid 
06.01.2016Examination fee paid 
Examination procedure06.01.2016Examination requested  [2016/23]
30.08.2016Amendment by applicant (claims and/or description)
29.05.2017Despatch of a communication from the examining division (Time limit: M04)
28.09.2017Reply to a communication from the examining division
23.03.2018Communication of intention to grant the patent
28.06.2018Fee for grant paid
28.06.2018Fee for publishing/printing paid
28.06.2018Receipt of the translation of the claim(s)
Opposition(s)31.05.2019No opposition filed within time limit [2019/32]
Fees paidRenewal fee
27.07.2016Renewal fee patent year 03
24.07.2017Renewal fee patent year 04
23.07.2018Renewal fee patent year 05
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipHU17.07.2014
AL29.08.2018
CY29.08.2018
CZ29.08.2018
EE29.08.2018
FI29.08.2018
HR29.08.2018
LT29.08.2018
LV29.08.2018
MC29.08.2018
MK29.08.2018
MT29.08.2018
RO29.08.2018
RS29.08.2018
SI29.08.2018
SK29.08.2018
SM29.08.2018
BG29.11.2018
GR30.11.2018
IS29.12.2018
[2022/31]
Former [2021/34]HU17.07.2014
AL29.08.2018
CY29.08.2018
CZ29.08.2018
EE29.08.2018
FI29.08.2018
HR29.08.2018
LT29.08.2018
LV29.08.2018
MC29.08.2018
MT29.08.2018
RO29.08.2018
RS29.08.2018
SI29.08.2018
SK29.08.2018
SM29.08.2018
BG29.11.2018
GR30.11.2018
IS29.12.2018
Former [2021/32]HU17.07.2014
AL29.08.2018
CY29.08.2018
CZ29.08.2018
EE29.08.2018
FI29.08.2018
HR29.08.2018
LT29.08.2018
LV29.08.2018
MC29.08.2018
RO29.08.2018
RS29.08.2018
SI29.08.2018
SK29.08.2018
SM29.08.2018
BG29.11.2018
GR30.11.2018
IS29.12.2018
Former [2021/26]AL29.08.2018
CY29.08.2018
CZ29.08.2018
EE29.08.2018
FI29.08.2018
HR29.08.2018
LT29.08.2018
LV29.08.2018
MC29.08.2018
RO29.08.2018
RS29.08.2018
SI29.08.2018
SK29.08.2018
SM29.08.2018
BG29.11.2018
GR30.11.2018
IS29.12.2018
Former [2020/14]AL29.08.2018
CZ29.08.2018
EE29.08.2018
FI29.08.2018
HR29.08.2018
LT29.08.2018
LV29.08.2018
MC29.08.2018
RO29.08.2018
RS29.08.2018
SI29.08.2018
SK29.08.2018
SM29.08.2018
BG29.11.2018
GR30.11.2018
IS29.12.2018
Former [2019/37]AL29.08.2018
CZ29.08.2018
EE29.08.2018
FI29.08.2018
HR29.08.2018
LT29.08.2018
LV29.08.2018
RO29.08.2018
RS29.08.2018
SI29.08.2018
SK29.08.2018
SM29.08.2018
BG29.11.2018
GR30.11.2018
IS29.12.2018
Former [2019/27]AL29.08.2018
CZ29.08.2018
EE29.08.2018
FI29.08.2018
HR29.08.2018
LT29.08.2018
LV29.08.2018
RO29.08.2018
RS29.08.2018
SK29.08.2018
SM29.08.2018
BG29.11.2018
GR30.11.2018
IS29.12.2018
Former [2019/24]AL29.08.2018
CZ29.08.2018
EE29.08.2018
FI29.08.2018
HR29.08.2018
LT29.08.2018
LV29.08.2018
RO29.08.2018
RS29.08.2018
SK29.08.2018
BG29.11.2018
GR30.11.2018
IS29.12.2018
Former [2019/22]AL29.08.2018
CZ29.08.2018
FI29.08.2018
HR29.08.2018
LT29.08.2018
LV29.08.2018
RO29.08.2018
RS29.08.2018
BG29.11.2018
GR30.11.2018
IS29.12.2018
Former [2019/12]AL29.08.2018
FI29.08.2018
HR29.08.2018
LT29.08.2018
LV29.08.2018
RS29.08.2018
BG29.11.2018
GR30.11.2018
IS29.12.2018
Former [2019/11]FI29.08.2018
HR29.08.2018
LT29.08.2018
RS29.08.2018
BG29.11.2018
GR30.11.2018
IS29.12.2018
Former [2019/08]FI29.08.2018
LT29.08.2018
IS29.12.2018
Former [2019/07]LT29.08.2018
Cited inInternational search[XDY]WO9920260  (EUROGENE LIMITED [GB], et al) [XD] 1-3,11-15 * abstract * * page 8, line 30 - page 9, line 1 * * claim - * [Y] 11-15;
 [XDY]WO0021509  (IMP COLLEGE INNOVATIONS LTD [GB], et al) [XD] 1-3,11-15 * abstract * * claim - * [Y] 11-15;
 [A]WO02096883  (VICORE PHARMA AB [SE], et al) [A] 1-15 * abstract * * claim - *;
 [A]WO2006109048  (VICORE PHARMA AB [SE], et al) [A] 1-15 * abstract * * claim - *;
 [X]WO2007083119  (IMP INNOVATIONS LTD [GB], et al) [X] 1-3 * abstract * * claim - *;
 [A]US2012035232  (STECKELINGS ULRIKE [DE], et al) [A] 1-15 * abstract * * claim - *;
 [X]  - YAO-HUA SONG ET AL, "Muscle-specific expression of IGF-1 blocks angiotensin II-induced skeletal muscle wasting", JOURNAL OF CLINICAL INVESTIGATION, (20050113), vol. 115, no. 2, doi:10.1172/JCI200522324, ISSN 0021-9738, pages 451 - 458, XP055070991 [X] 1-3 * abstract * * page 453; figure 3 *

DOI:   http://dx.doi.org/10.1172/JCI200522324
 [X]  - SPRINGER J ET AL, "The Xanthine Oxidase Inhibitors Oxypurinol and Allopurinol Reduce Wasting and Improve Cardiac Function in Experimental Cancer Cachexia", JOURNAL OF CARDIAL FAILURE, CHURCHILL LIVINGSTONE, NAPERVILLE, IL, US, vol. 15, no. 6, ISSN 1071-9164, (20090801), page S22, (20090730), XP026390505 [X] 1-3 * abstract *
 [XY]  - K. KURODA ET AL, "Prevention of Cancer Cachexia by a Novel Nuclear Factor B Inhibitor in Prostate Cancer", CLINICAL CANCER RESEARCH, (20050801), vol. 11, no. 15, doi:10.1158/1078-0432.CCR-04-2561, ISSN 1078-0432, pages 5590 - 5594, XP055080283 [X] 1-3 * abstract * [Y] 1-15

DOI:   http://dx.doi.org/10.1158/1078-0432.CCR-04-2561
 [XY]  - JAD R. MAAMARY ET AL, "574. Models of Cancer Cachexia: Treatment with Inhibition of NF-kB", MOLECULAR THERAPY, (20060501), vol. 13, doi:10.1016/j.ymthe.2006.08.647, ISSN 1525-0016, pages S221 - S221, XP055080284 [X] 1-3 * abstract * [Y] 1-15

DOI:   http://dx.doi.org/10.1016/j.ymthe.2006.08.647
 [XY]  - MIREIA OLIVAN ET AL, "Theophylline is able to partially revert cachexia in tumour-bearing rats", NUTRITION & METABOLISM, BIOMED CENTRAL. LONDON, GB, (20120821), vol. 9, no. 1, doi:10.1186/1743-7075-9-76, ISSN 1743-7075, page 76, XP021122176 [X] 1-3 * abstract * * page 80, column r, paragraph last - page 81, column l, paragraph 1; figure 4 * [Y] 1-15

DOI:   http://dx.doi.org/10.1186/1743-7075-9-76
 [XY]  - KUNG THOMAS ET AL, "Novel treatment approaches to cachexia and sarcopenia: highlights from the 5th Cachexia Conference", EXPERT OPINION ON INVESTIGATIONAL DRUGS, ASHLEY PUBLICATIONS LTD., LONDON, GB, (20100401), vol. 19, no. 4, doi:10.1517/13543781003724690, ISSN 1354-3784, pages 579 - 585, XP008123842 [X] 1-3 * abstract * * page 582, column r, paragraph last - page 583, column l, paragraph 1 * [Y] 1-15

DOI:   http://dx.doi.org/10.1517/13543781003724690
 [XY]  - JOSEP M ARGILÉS ET AL, "Optimal management of cancer anorexia-cachexia syndrome", CANCER MANAGEMENT AND RESEARCH, (20100122), vol. 2, no. 1, ISSN 1179-1322, pages 27 - 38, XP055069782 [X] 1-3 * abstract * * page 31, column l, paragraph last - page 32, column l, paragraph 3 * [Y] 1-15
 [Y]  - F. ROMPE ET AL, "Direct Angiotensin II Type 2 Receptor Stimulation Acts Anti-Inflammatory Through Epoxyeicosatrienoic Acid and Inhibition of Nuclear Factor B", HYPERTENSION, (20100401), vol. 55, no. 4, doi:10.1161/HYPERTENSIONAHA.109.147843, ISSN 0194-911X, pages 924 - 931, XP055080304 [Y] 1-15 * the whole document *

DOI:   http://dx.doi.org/10.1161/HYPERTENSIONAHA.109.147843
 [Y]  - U MUSCHA STECKELINGS ET AL, "Non-peptide AT2-receptor agonists", CURRENT OPINION IN PHARMACOLOGY, (20110401), vol. 11, no. 2, doi:10.1016/j.coph.2010.11.002, ISSN 1471-4892, pages 187 - 192, XP055080308 [Y] 1-15 * abstract * * page 190; figure 2 * * page 191, column l, paragraphs 2-3 *

DOI:   http://dx.doi.org/10.1016/j.coph.2010.11.002
 [Y]  - E. KASCHINA ET AL, "Angiotensin II Type 2 Receptor Stimulation: A Novel Option of Therapeutic Interference With the Renin-Angiotensin System in Myocardial Infarction?", CIRCULATION, (20081209), vol. 118, no. 24, doi:10.1161/CIRCULATIONAHA.108.784868, ISSN 0009-7322, pages 2523 - 2532, XP055080309 [Y] 1-15 * abstract * * point 3; page 2528, column r *

DOI:   http://dx.doi.org/10.1161/CIRCULATIONAHA.108.784868
 [Y]  - KOUSEI OHSHIMA ET AL, "Direct Angiotensin II Type 2 Receptor Stimulation Ameliorates Insulin Resistance in Type 2 Diabetes Mice with PPAR[gamma] Activation", PLOS ONE, (20121114), vol. 7, no. 11, doi:10.1371/journal.pone.0048387, ISSN 1932-6203, page e48387, XP055080311 [Y] 1-15 * abstract * * page 3, column r, paragraph 3 * * page 4, column r, paragraph last * * page 8; figure 6 *

DOI:   http://dx.doi.org/10.1371/journal.pone.0048387
 [Y]  - L. C. MATAVELLI ET AL, "Angiotensin AT2 Receptor Stimulation Inhibits Early Renal Inflammation in Renovascular Hypertension", HYPERTENSION, (20110201), vol. 57, no. 2, doi:10.1161/HYPERTENSIONAHA.110.164202, ISSN 0194-911X, pages 308 - 313, XP055080312 [Y] 1-15 * abstract * * figure 2 *

DOI:   http://dx.doi.org/10.1161/HYPERTENSIONAHA.110.164202
 [A]  - XIONGYU WU ET AL, "Selective Angiotensin II AT2 Receptor Agonists: Arylbenzylimidazole Structure-Activity Relationships", JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY, (20061109), vol. 49, no. 24, doi:10.1021/JM0606185, ISSN 0022-2623, pages 7160 - 7168, XP008126707 [A] 1-15 * abstract * * page 7163; table 1; compound 11 * * page 7165; table 2; compound 51 *

DOI:   http://dx.doi.org/10.1021/jm0606185
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.